My thoughts on Sing Medical Group’s possible share transaction (29 Dec 20)

Dear all Sing Medical Group (“SMG”) announced on 18 Dec 20 that the Company is currently in discussions with a third party regarding a possible transaction involving the Company’s shares. The discussions are preliminary and there is no certainty or assurance that such discussions will progress beyond the current stage or that any transaction will materialise as a result of such discussions.   Why am I interested in SMG? My personal view is that at $0.315, given a potential share transaction scenario, the risk reward seems favourable. Please refer to my basis and the risks as highlighted below: 1) Past […]

6 concerns investors have with Midas (7 Apr 17)

Midas has slumped 14% post a 76% growth in its FY16 results. It closed at $0.225 on 7 Apr 2017 which was near the all-time closing low of $0.210. Some of my high net worth clients have told me their concerns on Midas. I have since met Mr Patrick Chew, CEO of Midas and Mr Liaw Kok Feng, CFO Midas for a 1-1 discussion. Here are my key takeaways.   Key takeaways from my concerns posed to the management Concern 1: Orders momentum have slowed for its aluminium extrusion segment According to management, they remain positive for their aluminium extrusion […]